Mumbai-based JB Chemicals and Pharmaceuticals on July 30 reported solid growth across key financial metrics in the first quarter of FY26. The company’s net profit rose 14.4% year-on-year to ₹202.3 crore compared to ₹176.8 crore in the same period last year.
The firm’s revenue increased 8.9% to ₹1,093 crore while the earnings before interest, taxes, depreciation, and amortisation (EBITDA) spiked to ₹301.8 crore from ₹280.7 crore last year. The margins remained almost flat at 27.5% compared to 27.9% a year ago.
“JB continues to be the fastest growing domestic pharma company amongst top 25 organisations as per IQVIA MAT June ’25 data. The domestic business recorded approximately 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands & their franchises are also performing well,” Nikhil Chopra, CEO and Wholetime Director of JB Pharma, said.
The company’s revenue from the domestic formulations business stood at ₹678 crore, a 14% growth over last year. But, revenue from its international business declined marginally to ₹283 crore from ₹290 crore in the first quarter a year ago.
Meanwhile, the company’s other expenses increased by 16% to ₹252 crore primarily on account of one-off charges due to the proposed merger scheme.
On June 29, Torrent Pharmaceuticals announced the acquisition of majority stake in JB Chemicals and Pharmaceuticals in a ₹19,500-crore deal. Under the proposed deal, Torrent will acquire 46.39% stake from the promoters for about ₹11,917 crore. It would additionally buy 2.80% stake from certain employees of JB Chemicals at the same acquisition price of ₹1,600 per share.
Also read: Torrent Pharma to acquire additional 2.41% stake in JB Chemicals for ₹620 crore
Shares of JB Chemicals closed at ₹1,782.9down 1.1% or ₹19.55, on the BSE today (July 30).
